Catalyst Pharma (CPRX)
NASDAQ:CPRX
Want to see CPRX full AI Analyst Report?
CPRX Stock Chart & Stats
$26.26
-$0.35(-1.79%)
At close: 4:00 PM EST
$26.26
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $32.56
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.18M
Market Cap
$3.51B
Enterprise Value$2.83B
Total Cash (Recent Filing)$709.17M
Total Debt (Recent Filing)$2.79M
Price to Earnings (P/E)13.3
Beta0.70
Next Earnings
May 13, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.75
Shares Outstanding122,123,886
10 Day Avg. Volume1,455,369
30 Day Avg. Volume1,180,364
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)2.99
Price to Sales (P/S)4.85
P/FCF Ratio13.68
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue4.80
Enterprise Value/Gross Profit5.64
Enterprise Value/Ebitda9.03
Forecast
1Y Price Target
$34.50Price Target Upside31.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.88
Revenue Forecast (FY)$630.64M
Bulls Say, Bears Say
Bulls Say
Corporate DevelopmentManagement's pursuit of external business development combined with internal life-cycle management provides multiple pathways for inorganic and organic growth.
Patent EstateA strong patent estate together with competitors' manufacturing challenges creates a protective competitive position that could support upside if market dynamics shift favorably.
Royalty ObligationsScheduled reductions in royalty obligations for Firdapse are expected to improve reported revenues and margins and help offset higher selling expenses.
Bears Say
Financing ConstraintsA limited willingness to use debt for clinical-stage opportunities constrains the ability to finance higher-risk, potentially transformative development programs.
Generic CompetitionGeneric competition is eroding sales of Fycompa, reducing that product's contribution to future revenue and pressuring overall top-line growth.
Reimbursement PressureMedicare Part D related gross-to-net pressures are expected to increase and create headwinds for reported revenue and profitability.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $19.05 and its highest was $32.56 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $3.51B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is May 13, 2026 which is in 8 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Feb 26, 2026. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.344 by $0.066.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.46.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 122,123,886 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.41 in its last earnings report, beating expectations of $0.344. Following the earnings report the stock price went down -7.235%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.50 (31.38% Upside)
$34.50 (31.38% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 236.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.60%
12-Months-Change
Fundamentals
Return on Equity
24.32%
Trailing 12-Months
Asset Growth
29.53%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive performance narrative: strong double-digit revenue growth, record product and portfolio performance (notably FIRDAPSE and AGAMREE), robust profitability and cash generation, clear commercial execution improvements (patient identification, diagnostics, enrollment, and retention), and a constructive 2026 guidance range. Challenges were acknowledged—FYCOMPA's loss of exclusivity and revenue erosion, ongoing patent litigation, increasing royalties/milestones and gross-to-net pressure from IRA, and the need for additional label-supporting data for AGAMREE—all of which are being actively managed. On balance, highlights meaningfully outweigh the lowlights.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$34.50
▲(31.38% Upside)
Technical Analysis
Ownership Overview
5.59% Insiders
18.27% Mutual Funds
2.13% Other Institutional Investors
46.23% Public Companies and Individual Investors